Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
暂无分享,去创建一个
P. Fumoleau | C. Hill | P. Fargeot | J. Misset | P. Chollet | G. Mathé | D. Belpomme | M. di Palma | B. Le Mével | R. Plagne | J. Guerrin | M. Delgado | R. Metz | M. Ithzaki | M. Di Palma
[1] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[2] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[3] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[4] G Marini,et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse , 1994, The Lancet.
[5] S. Ebbs,et al. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. , 1993, British Journal of Cancer.
[6] L. Mauriac,et al. Original article: Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen , 1992 .
[7] G. Bonadonna,et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Bonadonna,et al. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Redmond,et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] I. Tannock,et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Misset,et al. Consistencies and variations of observations during serial analyses of a trial of adjuvant chemotherapy in breast cancer , 1987 .
[13] G. Bonadonna,et al. Second malignancies after CMF for resectable breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Levine,et al. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Gelman,et al. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Bonadonna,et al. Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.
[17] R. Nissen-Meyer,et al. Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer , 1978, Cancer.
[18] G. Hortobagyi,et al. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. , 1976, British medical journal.
[19] G. Bonadonna,et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.
[20] C. Redmond,et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.